Category Archives: Mesenchymal Cell

Mesenchymal Cell News is an online publication and email newsletter that delivers updates on the latest research in the mesenchymal stem cell field.
Subscribe
Mesenchymal Cell News is a weekly email newsletter covering topics such as the isolation, identification, and culturing conditions of mesenchymal stem cells, as well as their cellular characterization, behavior and differentiation capacities. We also include research that focuses on identifying tissue sources of mesenchymal stem cells and their potential therapeutic applications in regenerative medicine and cellular therapies.

Mtu1 Defects Are Correlated with Reduced Osteogenic Differentiation

Accumulating evidence has revealed that mitochondria dynamics and function regulation is essential for the successful (MSC differentiation. Researchers reported for the first time that Mtu1 defects are correlated with reduced osteogenic differentiation.
[Cell Death & Disease]
He, Q., Zhao, Q., Li, Q., Pan, R., Li, X., & Chen, Y. (2021). Mtu1 defects are correlated with reduced osteogenic differentiation. Cell Death & Disease, 12(1), 1–12. https://doi.org/10.1038/s41419-020-03345-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

ALKBH5 Suppresses Tumor Progression via an m6A-Dependent Epigenetic Silencing of Pre-miR-181b-1/Yap Signaling Axis in Osteosarcoma

The authors explored the potential involvement of ALKBH5 in osteosarcoma and deciphered the underlying cellular/molecular mechanisms. They discovered downregulated levels of demethylase ALKBH5 were correlated with increased m6A methylation in osteosarcoma cells/tissues compared with normal osteoblasts cells/tissues.
[Cell Death & Disease]
Yuan, Y., Yan, G., He, M., Lei, H., Li, L., Wang, Y., He, X., Li, G., Wang, Q., Gao, Y., Qu, Z., Mei, Z., Shen, Z., Pu, J., Wang, A., Zhao, W., Jiang, H., Du, W., & Yang, L. (2021). ALKBH5 suppresses tumor progression via an m 6 A-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma. Cell Death & Disease, 12(1), 1–16. https://doi.org/10.1038/s41419-020-03315-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

Bone Therapeutics Treats First Patient in ALLOB Phase IIb Tibial Fracture Study

Bone Therapeutics announced it has treated the first patient for the ALLOB Phase IIb clinical study in patients with difficult-to-heal tibial fractures. The successful completion of Bone Therapeutics’ ALLOB trials would further demonstrate the promise of mesenchymal stromal derived cell therapies for the treatment of other underserved conditions.
[Bone Therapeutics]
Press Release
Bookmark

No account yet? Register

0
Share

Defining Human Mesenchymal and Epithelial Heterogeneity in Response to Oral Inflammatory Disease

Using single-cell transcriptome profiling, scientists reveal a striking remodelling of the epithelial and mesenchymal niches with a decrease in functional populations that are linked to the aetiology of chronic inflammatory disease.
[eLife]
Caetano, A. J., Yianni, V., Volponi, A., Booth, V., D’Agostino, E. M., & Sharpe, P. (2021). Defining human mesenchymal and epithelial heterogeneity in response to oral inflammatory disease. ELife, 10, e62810. https://doi.org/10.7554/eLife.62810 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Feasibility of Reduced-Dose Posttransplant Cyclophosphamide and Cotransplantation of Peripheral Blood Stem Cells and Umbilical Cord-Derived Mesenchymal Stem Cells for SAA

Scientists evaluated the effectiveness and safety of reduced-dose cyclophosphamide, 20 mg/kg for 13 patients in matched sibling donor hematopoietic stem cell transplantation (HSCT) cohort and 25 mg/kg for 22 patients in haplo-HSCT cohort, on days +3, +4 combined with cotransplantation of peripheral blood stem cells and human umbilical cord-derived MSCs for severe aplastic anemia (SAA).
[Scientific Reports]
Zu, Y., Zhou, J., Fu, Y., Fang, B., Liu, X., Zhang, Y., Yu, F., Zuo, W., Zhou, H., Gui, R., Li, Z., Liu, Y., Zhao, H., Zhang, C., & Song, Y. (2021). Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA. Scientific Reports, 11(1), 253. https://doi.org/10.1038/s41598-020-80531-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Extracellular Vesicle-Associated Repetitive Element DNAs As Candidate Osteosarcoma Biomarkers

Osteosarcoma (OS) is the most common malignant bone tumor in children and young adults. Despite high-risk factors being identified, no test for early detection is available. This study aimed to identify circulating nucleic acid sequences associated with serum extracellular vesicle preparations at the time of OS diagnosis, as a step towards an OS early detection assay.
[Scientific Reports]
Cambier, L., Stachelek, K., Triska, M., Jubran, R., Huang, M., Li, W., Zhang, J., Li, J., & Cobrinik, D. (2021). Extracellular vesicle-associated repetitive element DNAs as candidate osteosarcoma biomarkers. Scientific Reports, 11(1), 94. https://doi.org/10.1038/s41598-020-77398-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

YAP/TAZ Inhibition Reduces Metastatic Potential of Ewing Sarcoma Cells

Investigators suggest that YAP/TAZ pathway inhibition may prevent Ewing sarcoma (EwS) cell dissemination and metastasis, justifying further preclinical development of YAP/TAZ inhibitors for EwS treatment.
[Oncogenesis]
Bierbaumer, L., Katschnig, A. M., Radic-Sarikas, B., Kauer, M. O., Petro, J. A., Högler, S., Gurnhofer, E., Pedot, G., Schäfer, B. W., Schwentner, R., Mühlbacher, K., Kromp, F., Aryee, D. N. T., Kenner, L., Uren, A., & Kovar, H. (2021). YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. Oncogenesis, 10(1), 1–13. https://doi.org/10.1038/s41389-020-00294-8 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Microvascular Density, Endothelial Area, and Ki-67 Proliferative Index Correlate Each Other in Cat Post-Injection Fibrosarcoma

Scientists conducted a crossing study evaluating microvascular density, endothelial area, and Ki-67 proliferative index was reported for a series of formalin-fixed and paraffin-embedded tissue samples from 99 cat patients, affected by cat post-injection fibrosarcoma, by using a till ×400 magnification light microscopy.
[Cells]
Patruno, R., Passantino, G., Laface, C., Tinelli, A., Zito, A., Ruggieri, R., Luposella, F., Gadaleta, P., Laforgia, M., Lacitignola, L., Ammendola, M., Ranieri, G., & Zizzo, N. (2021). Microvascular Density, Endothelial Area, and Ki-67 Proliferative Index Correlate Each Other in Cat Post-Injection Fibrosarcoma. Cells, 10(1), 31. https://doi.org/10.3390/cells10010031 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Adiponectin Signaling in Bone Homeostasis, with Age and in Disease

The authors explore the current literature on adiponectin in bone, looking in depth at the comparison between human and murine data in health, with age and in disease.
[Bone Research]
Lewis, J. W., Edwards, J. R., Naylor, A. J., & McGettrick, H. M. (2021). Adiponectin signalling in bone homeostasis, with age and in disease. Bone Research, 9(1), 1–11. https://doi.org/10.1038/s41413-020-00122-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

HUCMSCs Transplantation Combined with Ultrashort Wave Therapy Attenuates Neuroinflammation in Spinal Cord Injury through NUR77/ NF-κB Pathway

Low-dose Ultrashort Wave was treated one day after spinal cord injury (SCI) and human umbilical cord mesenchymal stem cell suspension was transferred to the lesion using a micro-syringe seven days after SCI.
[Life Sciences]
Wang, S., Jia, Y., Cao, X., Feng, S., Na, L., Dong, H., Gao, J., & Zhang, L. (2020). HUCMSCs transplantation combined with ultrashort wave therapy attenuates neuroinflammation in spinal cord injury through NUR77/ NF-κB pathway. Life Sciences, 118958. https://doi.org/10.1016/j.lfs.2020.118958 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Umbilical Cord Mesenchymal Stem Cells for COVID-19 Acute Respiratory Distress Syndrome: A Double-Blind, Phase I/IIa, Randomized Controlled Trial

Scientists determined the safety and explored efficacy of umbilical cord mesenchymal stem cell infusions in subjects with COVID‐19 scute respiratory distress syndrome. A double‐blind, Phase I/IIa, randomized, controlled trial was performed.
[Stem Cells Translational Medicine]
Lanzoni, G., Linetsky, E., Correa, D., Cayetano, S. M., Alvarez, R. A., Kouroupis, D., Gil, A. A., Poggioli, R., Ruiz, P., Marttos, A. C., Hirani, K., Bell, C. A., Kusack, H., Rafkin, L., Baidal, D., Pastewski, A., Gawri, K., Leñero, C., Mantero, A. M. A., … Ricordi, C. (n.d.). Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. STEM CELLS Translational Medicine, n/a(n/a). https://doi.org/https://doi.org/10.1002/sctm.20-0472 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share